EN | UA
EN | UA

Help Support

Back

Which is more effective for treating HCV: Sofosbuvir + Daclatasvir or Sofosbuvir alone?

Hepatitis Hepatitis
Hepatitis Hepatitis

What's new?

In people with hepatitis C virus infection, Sofosbuvir plus Daclatasvir is a more efficient therapy when compared to Sofosbuvir alone.

According to a study published in "Journal Of Pharmaceutical Negative Results", dialysis-dependent chronic hepatitis C patients treated with Sofosbuvir + Daclatasvir had greater treatment effectiveness at 3 and 6 months of treatment as opposed to those treated with Sofosbuvir alone. For hepatitis C virus (HCV) management, researchers compared the effectiveness of Sofosbuvir + Daclatasvir versus Sofosbuvir alone.

Treatment naïve patients of either gender (n = 108) receiving hemodialysis and suffering from HCV were included in this randomized controlled trial. All the volunteers had HCV RNA levels ≥100,000 IU/mL and ranged in age from 18 to 65 years. By using the lottery approach, all of the recruited candidates were randomized into 2 groups. In the dialysis department, people in Group A received Sofosbuvir and Daclatasvir together, whereas those in Group B received Sofosbuvir alone.

Viral load estimated at three months and sustained virological response at six months were used to assess the study's results. Group A had 50.0% of men (n=27/54) and 50.0% of females (n=27/54) whereas group B contained 53.7% of males (n=29/54) and 46.3% of females (n=25/54).

Subjects in group A had a mean age of 42.8 years ± 12.1 standard deviation (SD), whereas those in group B had a mean age of 47.2 years ± 10.7 SD. The mean duration of dialysis was 24.3 years ± 17.3 SD for group B candidates and 28.3 months ± 25.7 SD for group A volunteers.

In group A, 7.4% (n=4/54) had no baseline comorbidity, 5.6% (n=3/54) exhibited hypertension, 55.6% (n=30/54) suffered from diabetes, 1.9% (n=1/54) had ischemic heart disease, and 29.6% (n=16/54) had multiple comorbidities at the baseline. In group B, the percentages were as follows: 14.8% (n=8/54), 1.9% (n=1/54), 53.7% (n=19/54), 1.9% (n=1/54), and 27.8% (n=15/54). Notably, 98.1% (n=53/54) of subjects in group A and 96.3% (n=52/54) of patients in group B did not have viral load three months after the commencement of the therapy.

Sustained virological response was attained in 98.1% (n=53/54) of subjects in group A and 96.3% (n=52/54) of subjects in group B six months after the commencement of therapy. For the treatment of HCV infection, combination therapy with Sofosbuvir and Daclatasvir was superior to monotherapy with Sofosbuvir at 3 and 6 months. However, there was no clinically meaningful difference.

Source:

Journal of Pharmaceutical Negative Results

Article:

Comparison Of Sofosbuvir Plus Daclatsvir With Sofosbuvir Alone In Achieving Svr In Dialysis Dependent Chronic Hepatitis C Patients

Authors:

Dr. Asma Hafeez et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: